Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levobupivacaine vs Exparel (liposomal bupivacaine) for pain and disability in lateral epicondylitis
2018-001191-38Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine and levobupivacaine in Lateral Epicondylitis (LET) (2 arms), sponsored by Turku University Hospital. Primary endpoint: Pain reduction by VAS. Started Jan 2020; status: completed.
02
Drugs
bupivacainelevobupivacaine
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on 2018-001191-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001191-38.